Medicare Enrolled
Dr. Rajesh Iyengar, MD
Family Medicine · Chicago, IL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Iyengar from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Iyengar?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Iyengar
Dr. Rajesh Iyengar is a family medicine specialist in Chicago, IL, with 20 years of NPI registration. Based on federal Medicare data, Dr. Iyengar performed 17,664 Medicare services across 14,688 unique beneficiaries.
Between the years covered by Open Payments, Dr. Iyengar received a total of $336 from 5 pharmaceutical and/or device companies across 18 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in family medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Iyengar is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 0% volume in IL
$336 industry payments
Medicare Practice Summary
Medicare Utilization ↗17,664
Medicare services
Top 0% in IL for family medicine
14,688
Unique beneficiaries
$62
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~883 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| COVID-19 vaccine administration Administration of a single dose of the coronavirus vaccine. |
2,562 | $42 | $50 |
| COVID-19 vaccine (Moderna bivalent) An intramuscular injection of the SARS-CoV-2 vaccine containing 50 micrograms in a 0.5 mL dose. |
2,339 | $143 | $220 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
1,985 | $32 | $40 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
1,905 | $65 | $185 |
| COVID-19 vaccine administration at home Administration of the COVID-19 vaccine at the patient's residence. This code is reported only once per individual home per date of service when only vaccine administration is performed. |
1,646 | $38 | $40 |
| Flu vaccine, quadrivalent A flu shot containing four strains of the influenza virus to help prevent seasonal influenza infection. |
1,521 | $76 | $120 |
| Adm sarscv2 bvl 50mcg/.5ml a | 858 | $43 | $45 |
| SARS-CoV-2 vaccine, 50 mcg/0.5 mL Administration of a SARS-CoV-2 vaccine containing 50 micrograms of antigen in a 0.5 milliliter dose. |
850 | $0 | $5 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
656 | $99 | $265 |
| Quadrivalent influenza vaccine, cell culture-derived A flu shot that protects against four strains of the influenza virus. It is produced using cell culture technology rather than traditional egg-based methods. |
497 | $32 | $50 |
| SARS-CoV-2 vaccine, 30 mcg/0.3 mL Administration of the SARS-CoV-2 (COVID-19) vaccine containing 30 micrograms of antigen in a 0.3 milliliter dose. |
399 | $43 | $45 |
| SARS-CoV-2 vaccine, 30 mcg/0.3 mL A vaccine injection to protect against the SARS-CoV-2 virus. The dose contains 30 micrograms of antigen in a 0.3 milliliter volume. |
394 | $0 | $5 |
| COVID-19 mRNA vaccine booster injection Intramuscular injection of a 30 mcg booster dose of the mRNA-based COVID-19 vaccine. The vaccine is preservative-free and reconstituted with diluent prior to administration. |
243 | $43 | $48 |
| Nursing facility visit, high complexity A follow-up visit by a healthcare provider at a nursing facility for an established patient. The visit involves a high level of medical decision making and takes at least 45 minutes. |
220 | $127 | $250 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
196 | $42 | $136 |
| COVID-19 vaccine (Pfizer bivalent) Administration of a 30 mcg dose of the SARS-CoV-2 vaccine via intramuscular injection. |
187 | $128 | $200 |
| COVID-19 mRNA vaccine injection An intramuscular injection of a coronavirus vaccine using mRNA technology to help prevent COVID-19. |
151 | $0 | $5 |
| Pneumonia vaccine administration This procedure involves the injection of a vaccine to protect against pneumococcal disease. It is administered by a healthcare provider. |
123 | $32 | $40 |
| Pneumococcal conjugate vaccine (PCV20) An intramuscular injection of the 20-valent pneumococcal conjugate vaccine. It is used to protect against diseases caused by Streptococcus pneumoniae bacteria. |
106 | $283 | $303 |
| Quadrivalent influenza vaccine, cell-culture derived A flu shot containing four strains of influenza virus, produced using cell culture technology rather than eggs. This formulation is free from preservatives and antibiotics. |
93 | $33 | $50 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
89 | $11 | $27 |
| Nursing facility visit, established patient, straightforward A follow-up visit by a healthcare provider at a nursing facility for an established patient. The visit involves straightforward medical decision making and lasts at least 10 minutes. |
79 | $32 | $140 |
| Hospital discharge management, 30+ min This service covers the care provided by a physician or qualified healthcare professional on the day a patient is discharged from the hospital. It requires more than 30 minutes of total time spent on the day of discharge. |
75 | $96 | $350 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
64 | $145 | $441 |
| COVID-19 mRNA vaccine injection, booster dose An intramuscular injection of a single booster dose of the mRNA-based COVID-19 vaccine. The vaccine contains 50 mcg of spike protein in a 0.5 ml preservative-free dosage. |
63 | $43 | $45 |
| Nursing facility visit, moderate complexity A follow-up visit by a healthcare provider at a nursing facility for an established patient. The visit involves moderate medical decision making and takes at least 30 minutes. |
57 | $88 | $205 |
| COVID-19 mRNA vaccine injection An intramuscular injection of a coronavirus vaccine using mRNA technology to help prevent infection. |
53 | $0 | $5 |
| Nursing facility discharge management, more than 30 minutes This service involves care coordination and management activities performed by a healthcare professional to prepare a patient for discharge from a nursing facility. It requires more than 30 minutes of time spent on these activities. |
44 | $109 | $260 |
| Nursing facility visit, low complexity A daily follow-up visit for an existing patient in a nursing facility involving straightforward medical decision making. The visit requires at least 15 minutes of time if time is used to determine the level of care. |
42 | $62 | $175 |
| Initial nursing facility care, moderate complexity Initial care provided to a patient in a nursing facility with moderate medical decision making, taking at least 35 minutes. |
37 | $111 | $230 |
| COVID-19 mRNA vaccine booster injection Intramuscular injection of a 50 mcg booster dose of the mRNA-based COVID-19 vaccine. This administration is preservative-free and targets the spike protein. |
31 | $43 | $50 |
| First dose of mRNA COVID-19 vaccine injection This procedure involves the intramuscular injection of the first dose of a preservative-free mRNA-based COVID-19 vaccine. The dosage administered is 30 mcg in a 0.3ml volume. |
25 | $43 | $46 |
| Second dose of mRNA COVID-19 vaccine Intramuscular injection of the second dose of a preservative-free mRNA-based coronavirus vaccine. |
25 | $43 | $46 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
23 | $109 | $412 |
| COVID-19 mRNA vaccine injection An intramuscular injection of a coronavirus 2 vaccine using mRNA technology to help prevent infection. |
13 | $0 | $5 |
| Initial nursing facility care, high complexity An initial visit by a healthcare provider to a patient in a nursing facility involving a high level of medical decision making, lasting at least 45 minutes. |
13 | $151 | $280 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$336
Total received (2018-2024)
Avg $84/year across 4 years
Top 44% in IL for family medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
5
Companies
18
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$336 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$40
2023
$63
2019
$31
2018
$201
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Smith+Nephew, Inc.
$40
Top 3 companies account for 100.0% of 2024 payments
All-time payments by company (2018-2024) ›
Janssen Pharmaceuticals, Inc
$182
PFIZER INC.
$72
Smith+Nephew, Inc.
$40
Ferring Pharmaceuticals Inc.
$23
Sunovion Pharmaceuticals Inc.
$19
Top 3 companies account for 87.5% of all-time payments
Associated products mentioned in payments ›
CHANTIX · GRAFIX PL · INVOKANA · LONHALA MAGNAIR · REBYOTA · TRUMENBA · Utibron · XARELTO
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Family medicine physicians within 10 mi
2,781
Per 100K population
53.6
County median income
$81,797
Nearest hospital
ADVOCATE ILLINOIS MASONIC MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Iyengar is a mixed practice specialist, with above-average Medicare volume (top 0% in IL), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Iyengar experienced with covid-19 vaccine administration?
Based on Medicare claims data, Dr. Iyengar performed 2,562 covid-19 vaccine administration services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Iyengar receive payments from pharmaceutical companies?
Yes. Dr. Iyengar received a total of $336 from 5 companies across 18 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Iyengar's costs compare to other family medicine physicians in Chicago?
Dr. Iyengar's average Medicare payment per service is $62. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Iyengar) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Family Medicine
Common procedures, typical costs, and what industry payments mean in family medicine.
Same specialty & city
Family Medicine Physicians in Chicago
Browse family medicine physicians in Chicago ranked by procedure volume and transparency data.
Highest volume
Top Family Medicine Physicians in IL
Family medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Family Medicine Physicians in IL
Which IL family medicine physicians receive the most from drug and device companies.
By company
Janssen Pharmaceuticals, Inc Payments to Doctors
See all physicians who received payments from Janssen Pharmaceuticals, Inc.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Smith+Nephew, Inc. Payments to Doctors
See all physicians who received payments from Smith+Nephew, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology